Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach

Irina A. Denisova (), Tatiana V. Chubarova (), Irina E. Bogatova (), Sergey Vartanov (), Valerian G. Kucheryanu (), ViÑ tor M. Polterovich (), Natalia Turdyeva and Marina V. Shakleina ()
Additional contact information
Irina A. Denisova: Lomonosov Moscow State University, Moscow, Russia
Tatiana V. Chubarova: Institute of Economics RAS, Moscow, Russia
Irina E. Bogatova: Lomonosov Moscow State University, Moscow, Russia
Valerian G. Kucheryanu: Institute of General Pathology and Pathophysiology RAS, Moscow, Russia
ViÑ tor M. Polterovich: Central Economics and Mathematics Institute RAS, Moscow, Russia
Marina V. Shakleina: Lomonosov Moscow State University, Moscow, Russia
Authors registered in the RePEc Author Service: Виктор Меерович Полтерович

Population and Economics, 2020, vol. 4, issue 3, 111-127

Abstract: Neurodegenerative diseases, Parkinson disease among them, set challenges to modern societies both in terms of premature deaths and resources spent on treatment of the diseases. At that, preventive care and early diagnostics in particular are potential directions towards higher economic efficiency of healthcare interventions in this area. Authors of this paper suggest a modification of the cost-utility approach to evaluate economic efficiency of an early diagnostics at the presymptomatic (prodromal) stage of Parkinson disease (PD), when its symptoms do not appear clinically yet. Such diagnostics, in combination with neuroprotective therapy for persons at high risk of PD, allows postponing its development until later years, and thereby ensuring an improvement in the quality of life of the population, as well as saving resources of the healthcare system and society as a whole. The authors rely on the diagnostic approach proposed by the research group headed by M. Ugryumov, which is currently at the stage of laboratory testing. Its implementation potentially leads to savings in both direct and indirect costs for PD treatment compared to the traditional approach, but increases testing costs, and also requires the development of new neuroprotective therapy for identified risk groups. The authors propose a modification of the cost-benefit assessment procedure to take into account the uncertainty associated with the lack of a final understanding of the scope and composition of the testing group at the preclinical stage. The condition for the economic efficiency of the preclinical diagnostic method in the developed procedure is the minimum permissible probability of detecting an increased risk of PD in the test group. To test their algorithm, the authors carry out calculations basing on the Russian data.

Keywords: economic efficiency in healthcare; Parkinson disease; preclinical diagnostics; prodromal diagnostics; cost-utility approac (search for similar items in EconPapers)
JEL-codes: H43 I18 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://populationandeconomics.pensoft.net/article/59949/

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:arh:jpopec:v:4:y:2020:i:3:p:111-127

DOI: 10.3897/popecon.4.e59949

Access Statistics for this article

Population and Economics is currently edited by Irina E. Kalabikhina

More articles in Population and Economics from ARPHA Platform
Bibliographic data for series maintained by Teodor Georgiev ().